Pfizer Other Long-Term Assets 2012-2026 | PFE
Pfizer other long-term assets from 2012 to 2026. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Pfizer other long-term assets for the quarter ending March 31, 2026 were $9.317B, a 11.15% decline year-over-year.
- Pfizer other long-term assets for 2024 were $9.817B, a 21.28% decline from 2023.
- Pfizer other long-term assets for 2023 were $12.471B, a 5.26% decline from 2022.
- Pfizer other long-term assets for 2022 were $13.163B, a 71.42% increase from 2021.
|
Pfizer Annual Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024 | $9,817 |
| 2023 | $12,471 |
| 2022 | $13,163 |
| 2021 | $7,679 |
| 2020 | $4,879 |
| 2019 | $4,199 |
| 2018 | $2,799 |
| 2017 | $3,227 |
| 2016 | $3,323 |
| 2015 | $3,420 |
| 2014 | $3,513 |
| 2013 | $3,596 |
| 2012 | $3,233 |
| 2011 | $5,697 |
|
Pfizer Quarterly Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025-09-30 | $9,317 |
| 2025-06-30 | $9,455 |
| 2025-03-31 | $9,845 |
| 2024-12-31 | $9,817 |
| 2024-09-30 | $10,486 |
| 2024-06-30 | $10,710 |
| 2024-03-31 | $11,197 |
| 2023-12-31 | $12,471 |
| 2023-09-30 | $8,808 |
| 2023-06-30 | $13,028 |
| 2023-03-31 | $12,965 |
| 2022-12-31 | $13,163 |
| 2022-09-30 | $10,890 |
| 2022-06-30 | $7,659 |
| 2022-03-31 | $7,879 |
| 2021-12-31 | $7,679 |
| 2021-09-30 | $6,705 |
| 2021-06-30 | $6,056 |
| 2021-03-31 | $4,744 |
| 2020-12-31 | $4,879 |
| 2020-09-30 | $4,355 |
| 2020-06-30 | $4,327 |
| 2020-03-31 | $4,166 |
| 2019-12-31 | $4,199 |
| 2019-09-30 | $4,920 |
| 2019-06-30 | $4,388 |
| 2019-03-31 | $4,333 |
| 2018-12-31 | $2,799 |
| 2018-09-30 | $2,980 |
| 2018-06-30 | $2,896 |
| 2018-03-31 | $2,896 |
| 2017-12-31 | $3,227 |
| 2017-09-30 | $3,388 |
| 2017-06-30 | $3,466 |
| 2017-03-31 | $3,329 |
| 2016-12-31 | $3,323 |
| 2016-09-30 | $4,759 |
| 2016-06-30 | $4,618 |
| 2016-03-31 | $4,003 |
| 2015-12-31 | $3,420 |
| 2015-09-30 | $3,911 |
| 2015-06-30 | $3,635 |
| 2015-03-31 | $3,716 |
| 2014-12-31 | $3,513 |
| 2014-09-30 | $3,421 |
| 2014-06-30 | $3,574 |
| 2014-03-31 | $3,759 |
| 2013-12-31 | $3,596 |
| 2013-09-30 | $4,982 |
| 2013-06-30 | $5,143 |
| 2013-03-31 | $5,432 |
| 2012-12-31 | $3,233 |
| 2012-09-30 | $5,862 |
| 2012-06-30 | $5,806 |
| 2012-03-31 | $5,943 |
| 2011-12-31 | $5,697 |
| 2011-09-30 | $5,205 |
| 2011-06-30 | $4,761 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |